Barclays PLC Acquires 8,713 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Barclays PLC raised its stake in Zynex, Inc. (NASDAQ:ZYXI) by 43.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,821 shares of the company’s stock after acquiring an additional 8,713 shares during the quarter. Barclays PLC owned about 0.09% of Zynex worth $236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Hotchkis & Wiley Capital Management LLC increased its holdings in Zynex by 24.7% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares during the last quarter. Millennium Management LLC raised its holdings in Zynex by 66.5% during the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after buying an additional 118,615 shares during the period. Royce & Associates LP lifted its stake in Zynex by 9.2% in the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock valued at $2,099,000 after buying an additional 21,781 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Zynex by 1.6% in the second quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock valued at $1,797,000 after buying an additional 2,954 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after acquiring an additional 77,300 shares in the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZYXI. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Zynex in a research note on Friday, December 6th.

Zynex Price Performance

NASDAQ:ZYXI opened at $8.09 on Monday. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The firm’s 50-day simple moving average is $8.30 and its 200 day simple moving average is $8.36. The firm has a market cap of $257.63 million, a price-to-earnings ratio of 53.93 and a beta of 0.49. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. Zynex’s revenue was up .1% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. As a group, sell-side analysts predict that Zynex, Inc. will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $7.88, for a total value of $78,800.00. Following the completion of the transaction, the chief financial officer now directly owns 26,299 shares in the company, valued at approximately $207,236.12. This represents a 27.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 44,000 shares of company stock valued at $368,040. 52.13% of the stock is currently owned by corporate insiders.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.